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823-3 Oral Sirolimus for Recalc i t rant  In-Stent  Reetenosis 
Paul S. Teirstein. Jeffrey W. Moses, Mindy R. Fernandez, Prabhtaj Brara, Mark A. Grise, 
Mehren Moussavian, John P. Reiny, Martin B. Leon, Scripps Clinic, La Jolla, California, 
Lenox Hill Hospital, New York, New York. 
Background: Catheter-based radiation is an FDA approved treatment for in-stant rest- 
anosis, but not all patients are candidates for brachytherapy. Sirolimus-eluting stents are 
an effective therapy for restenosis, but this new device is currently not available to most 
patients in the United States. Oral sirolimus, however, is FDA-appreved to prevent rejec- 
tion after renal transplantation. We have offered oral sirolimus to selected "no-option" 
patients who are at especially high risk for recurrent restenosis. 
Methods: Patients were treated with a sirolimus loading dose of 6 mg 4-24 hours post- 
PTCA, followed by 2 rag/day for 4 weeks. A one month course of therapy was selected 
because in the RAVEL trial, efficacy was demonstrated using stants that delivered siroli- 
mus over a 4-6 week duration. For most patients, the cost of a 4-week drug regimen 
(about $400) was reimbursed by their insurance provider. Serum electrolytes, lipid pro- 
file, renal panel, and complete blood counts were measured at 1, 3, and 5 weeks after 
drug initiation. Patients are contacted monthly to determine adverse reactions, death, 
myocardial infarction, and need for repeat revascularization. 
Results: To date, 11 patients at high risk for restenosis have been treated with oral siroli- 
mus and patients are accruing at approximately 3/week. Indications included: failed radi- 
ation therapy = 7; lesion length too long for brachytherapy = 1; vessel diameter too small 
for brachytherapy = 3. The mean age was 57.6 +/- 11.8 and 63.6% were diabetic. The 
target lesion was the left anterior descending in 7 patients; right coronary in 0; and cir- 
cumflex in 2; radial graft to LAD in 1; saphenous vein graft to obtuse marginal branch in 
1. The mean number of previous restenoses per patient was 3.2 +/- 1.8. The mean time 
interval between the sirolimus treatment procedure and the immediately preceding 
revasculadzation procedure was 5.4 +/- 2.4 months. With very early follow-up, no 
adverse advents have occurred. 
Conclusion: Patients at extremely high risk for recurrent restenosis are receiving a 30- 
day course of oral sirolimus. Six-month follow-up results will be presented. 
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823-4 SCORE Trial Inter im Safety  Results: Despite Efficacy, 
Late Stent Thrombosis With the QuaDDS-QP2 Stent  
Eberhard Grubs. Karl Hauptmann, Antonio Colombo, Germano DiSciascio, Sigmund 
Silber, Roland Bach, Carlo DiMario, Nicholas Reifart, Jean Fajadet, Score investigators, 
He,'zzentrum Siegburg, Siegburg, Germany. 
Background: The purpose of the SCORES trial was to compare safety and efficacy of 
the QuaDDS-QP2 stent with control, bare stents (QueST or any bare metal stent) for 
treatment of de novo lesions. The QuaDDS-QP2 stent has 5 polymer sleeves that con- 
tain 4000 I~g of QP2, a taxane derivative intended to inhibit restenosis. QCA analysis 
(reported separately) showed improvements in restenosis despite including cases of 
stent thrombosis. The purpose of this abstract is analysis of long term clinical results 
reflecting high close taxane delivery using the sleeve technology. 
Methods: Of 400 planned patients at 15 sites, 266 patients were randomized and treated 
with either the QuaDDS-QP2 stant (N=128) or the QueST (112) or any bare metal slant 
(26)(Total control N=138). Enrollment was stopped due to increased early MACE events. 
Currently, 248 patients (120 QuaDDS; 128 QST) have completed the 6 month visit, 
including 18 patients that were lost to follow-up, dropped out or died. All MACE were 
adjudicated by a centralized Safety Adjudication Committee. 
Results: The QuaDDS group had 12 stant thromboses (four at least 6 months after stent 
placement; ten associated with MI) and 5 deaths (three associated with slant thrombosis, 
one with multi-organ failure post CABG, one with cardiogenic shock), 
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Parameter QuaDDS-QP2 QueST P value 
(N=128) (N=138) 
Stant Thrombosis 12 (9%) 0 <0,01 
Peri-procedural 1 
Discharge-Day 30 3 
Day 30-160 4 
After Day 180 4 
Death (cardiac-ralatad) 5 (4%) 0 0.02 
Conclusions: Early and late stent thromboses limit the utility of QuaDDS-QP2 stent 
despite its beneficial effect on restenosis. Likely explanations include high drug dose, 
sleeve capacity or sleeve properties. 
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823-5 Incidence of Incomplete Stent Apposition at Six Month 
Follow-Up in the Multi Center RAVEL Trial 
M. Degertekin, E, Regar, K. Tanabe, J. E. Sousa, A. Colombo, G. Guagliumi, J. L. 
Guermonprez, P. de Feyter, M. C. Morice, Patrick W. Serruvs, Thoraxcenter, Rotterdam, 
The Netherlands. 
Background: Patients with single de-novo lesions were randomized to receive 18 mm 
Sirolimus eluting stent (SES) Bx-VELOCITY tm or an uncoated stant (US) Bx- VELOCI- 
-~tm (Cordis). Most of incomplete stent appositions liSA)seen immediately after slant 
deployment resolve at 6-rnonth follow-up (FU). Since lack of intimal proliferation at 6- 
month has been described after SES implantation, we investigated the incidence and the 
clinical implication of ISA in the RAVEL study, a double-blinded controlled trial of SES 
versus US. Methods: In a subset of patients clinical, QCA and 3D IVUS FU was per- 
formed at 6-month. Based on the consensus of three independent analysts ISA was 
defined as >_1 strut cleady separated from vessel wall with evidence of blood speckles 
behind the strut. Percentage of neointimal hyperplasia (NIH) was calculated as neointi- 
real volume /stant volume. Late lumen loss was defined as MLD post procedure-MLD 
FU. Results: 
SES (n=50) US (n=49) p-value 
RD post (mm) 2,79 + 0.48 2.84 + 0.42 ns 
RD FU (ram) 2.82 _+ 0.51 2.48 _+ 0.42 < 0.001 
MLD post (mm) 2.47 _+ 0.43 2.46 + 0.39 ns 
MLD FU (mm) 2.40 + 0.49 1.55 + 0.59 < 0.001 
Late Loss (ram) 0.06 + 0.29 0.90 + 0.57 < 0.001 
TLR (%) 0 (0/50) 10 (5/49) < 0.001 
Late Occlusion (%) 0 (0/50) 0 (0/49) ns 
IVUS Lum.Vol.(mm 3) 125.4 + 33 94.1 ± 41,2 < 0.001 
IVUS NIH (%) 2.21 + 7.6 28.7 ± 21.3 < 0.001 
IVUS ISA 10 (20%) 2 (4%) < 0.015 
There were no significant differences in QCA and IVUS measurements between patients 
with or without ISA. 
Conclusion: The incidence of ISA in patients with SES at 6-month FU is significantly 
higher than with US. Since no IVUS was performed after deployment, we cannot con- 
clude whether this incomplete apposition is the persistence of early ISA without any tis- 
sue proliferation or the development of late tSA. Although ISA was not associated with 
adverse clinical events, long-term FU is needed to investigate the clinical implication of 
this IVUS observation. 
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823-6 Pacl i taxel  Coat ing  Reduces In-Stent Reatenoais: A 
Serial Volumetric Intravascular Ultrasound Analysis 
Mveono-Ki Hono. Gary S. Mintz, seong-wook Park, Jae-Joong Kim, Cheol Whan Lee, 
Neal E. Fearnot, William D. Vorhees, Nell J. Weissman, Seung-Jung Park, Asan Medical 
Center, University of U/san, Seoul, South Korea. 
Background: In-stent restenosis (ISR) is secondary to intimal hyperplasia (IH). Pacli- 
taxel inhibits microtubule formation rendering cells cytostatic; it inhibits restanosis in ani- 
mal models. The SupraG stent is a 316L stainless-stael slotted-tube design; stants are 
coated with pure paclitaxel that is attached to the metallic stent without a polymer. Meth- 
ods: ASPECT was a 3-center trial of paclitaxel-eluting stents vs placebo. 177 pts with 
single de novo or non-ISR lesions were randomized to placebo or low or high doses in a 
1:1:1 ratio. If a second stent was needed, then an uncoated stent was deployed. Pts 
were treated with antiplatelet agents for 6 rodS. The current intravascular ultrasound 
(IVUS) analysis was a single center substudy of ASPECT. Complete post-stent and fol- 
low-up IVUS was available in 81/102 pts: 25 control, 28 low dose, and 28 high dose. All 
stents were 15mm long; nominal diameters were 2.5-3.5mm. Cross-sectional analysis 
was performed every lmm; volumes were calculated using Simpson's rule. Results: 
IVUS findings are shown in the Table. With increasing doses, there was a stepwise 
reduction in follow-up IH volume (pANOVA<0.0001). Post-hoc analysis showed a 
decrease in iH volume when low dose was compared to control (p=0.012) and when high 
dose was compared to control (p<0.0001), but not when row and high doses were com- 
pared. Conclusions: Taxol-eluting stents are effective in reducing in-stsnt neointimal tis- 
sue proliferation and in-stent restenosis in man. 
Follow-up IVUS Results 
Control Low Dose Paclltaxel High Dose Paciltaxel 
Stent volume, mm 3 104±25 104±32 101±27 
Lumen volume, mm 3 72¢27 85±35 89±27 
IH volume, m m 3 31 ±22 18± t5 12± 14 
